Skip to main content

Cogent Biosciences, Inc Investor Event Transcript, Nov 17, 2026

Cogent Biosciences, Inc. (COGT)

Cogent Biosciences management says it expects FDA approval of bezuclastinib, with PDUFA dates of November 30th, December 30th and June 29th of 2027. Liver transaminase elevations are described as fluctuating, with no significant clinical sequelae. AI summary

Investor Event Transcript 2026-11-17 For: 2026-12-31
Added on November 17, 2026

Conference Transcript - COGT 2026-11-17

Faisal Khashid, Analyst — Jefferies

All right. Good afternoon, or I guess soon-to-be evening here in London, everyone. My name is Faisal Khashid, Senior Biotech Analyst at Jefferies. Really pleased to have with us today the management team of Cogent Bio. On stage with me is Andy Robbins. Andy, can I ask you to briefly introduce the company, please?

Andrew Robbins, Board Member

Sure. First of all, thanks, Faisal, for inviting us. We're happy to be here in London and meeting a great lineup of investors today. For those that aren't familiar with our story, Cogent Biosciences is... A company that's focused on the development of small molecule kinase inhibitors for patients with rare genetically driven diseases. Our lead asset is a drug known as bezuclastinib. It's a selective potent KIT inhibitor being developed for three distinct patient populations, the advanced and non-advanced forms of systemic mastocytosis, as well as imatinib-resistant gastrointestinal stromal tumors. Each of those patient populations, we ran a pivotal trial culminating with the results in 2025, All three were very positive with signs for high utility for use commercially in those patient groups. We've spent most of 2026 submitting and working, submitting NDAs and then working with the FDA on pending PDUFA action dates of November 30th, December 30th, and June 29th of 2027 for just non-advanced and advanced in that order. And so we're very excited. The other thing we've been doing this past year is preparing to launch the drug, so adding a number of commercial colleagues to the company, transitioning Cogent from a research and development organization into a fully integrated biopharmaceutical company. We are now very, very ready to launch the drug when we get the word from the FDA and hopefully bring beziclacinib to many, many patients in need of a new therapeutic. So maybe I'll pause there and see where you want to go next.

Faisal Khashid, Analyst — Jefferies

All right, great. So, Andy, we're kind of sitting here not too far away from your PDUFA date. Can you just give us an update to the extent possible and where things stand?

Andrew Robbins, Board Member

Yeah, we don't typically comment on the specific details of any discussions with regulatory agencies, so we'll wait until we get an approval. But we're expecting it. As I think folks may know, we're being reviewed under both breakthrough designation and real-time oncology review. The data from the peak study were about as unequivocal as you can get in a large Phase III cancer trial with a hazard ratio of 0.50 on the primary endpoint with a 16-and-a-half-month estimate for median progression-free survival relative to just over nine months for the control arm and a nearly doubling of objective response rate. The other really important part of the findings is that we showed that the average duration of therapy for patients on the combination now exceeds 21 months. That is relatively to the expectation prior to the peak study in second-line gist of about a seven- or an eight-month average duration of therapy. So this combination of bezuclacinib with sunitinib can really provide significant long-term benefit to patients.

Faisal Khashid, Analyst — Jefferies

Got it. So, Andy, you know we've got to talk about this. Investors have gotten kind of jittery about this idea of liver toxicity and what kind of warning language could come onto the label. Can you level set us on your expectations based on the data that we have today?

Andrew Robbins, Board Member

Yeah, well, we can tell you, and I've said this a few times, bezuclastinib, I think, is a very, at this point, very carefully and thoroughly characterized safety profile. When you look across our studies, whether you look at the Summit study at 100 milligram daily dose in non-advanced patients all the way up to the peak study using 600 milligrams of the same molecule in metastatic cancer patients with GIST, you see a very consistent safety profile where in sort of the order of the most frequent reported adverse events, As some patients experience changes in salty flavors as a taste, the next most prevalent adverse event would be their hair turning white, which is a very well-known characterized effect of an on-target KIT inhibitor. And then the most frequent adverse event, and in our case always reported as lab abnormalities, are fluctuating or elevated transaminases. What's most important in this profile is we are not associated with significant clinical sequelae in response to the elevated transaminases. So we don't have any patients with liver failure, liver transplant, any serious liver clinical adverse events, no Heiss law. So this truly, the profile is of fluctuating transaminases. And in all cases, the patients that have been treating with bezuclacinib, whether without any intervention, whether with dose reduction, or in very rare cases with dose discontinuation, have returned to baseline levels of transaminases. So that's the profile. We are happy to stipulate that patients who initiate on bezuclacinib should have liver monitoring. They should be tested with blood labs across these indications. It is the responsible thing to do. We also have talked to all oncologists, hematologists, complicated allergists who treat patients across these three indications. They all expect this as well and see no barrier to prescribing based on that profile.

Faisal Khashid, Analyst — Jefferies

Got it. And then with respect to specifics on the label itself, based on kind of your understanding of the profile you have and FDA precedent, would you expect this to be a situation where this is elevated to a black box warning, or is it something that would more likely sit in the warnings and precautions?

Andrew Robbins, Board Member

It's hard to predict until we have a final label, but if you're talking specifically about GIST, where our drug will be approved in combination with sunitinib, which has been the standard of care for the last 20-plus years around the world for second-line GIST patients, we politely point out that sunitinib itself has monitoring language, which suggests monthly monitoring for transaminase elevations, along with a box warning with, I would say, fairly substantial language relevant. That did not dissuade oncologists and sarcoma experts around the world from establishing it as the standard of care for these patients. So I don't know the answer specifically to your question of what will happen, but we know that the standard of care currently includes a box warning for hepatotoxicity with monitoring, and it is widely adopted in all patients coming off of imatinib resistance.

Faisal Khashid, Analyst — Jefferies

Got it. And then with respect to just this kind of regulatory question, you do point out that snitinib does have a box warning and this monitoring requirement for transaminases. Is there precedent of a box warning of the combo partner coming on to a new drug that's approved with that? Is there examples of the opposite? What does the precedent tell us here?

Andrew Robbins, Board Member

Yeah, we've done some work. You can find cases for both of the questions you've asked where it appears in labeling that a drug which is approved for the first time only in combination with another drug has some warnings and precaution or adverse event language brought over from the drug that it's approved in combination with. You can also easily find cases where that's not the case. So there doesn't seem to be a hard and fast rule from the FDA about how they apply this. I think that they look at the totality of the evidence from a clinical setting. They look at risk-benefit for the patient population. They probably look at a number of other factors. And most importantly, the individuals who are doing the review in different divisions of the FDA probably have different standards of how they apply this. So I wish that there was a rule in the CFR that told you exactly what's going to happen, but I don't think there is one.

Faisal Khashid, Analyst — Jefferies

Got it. Okay. And then investors have kind of developed this interesting idea that somehow getting a black box warning in the setting of GIST would somehow impair the SM opportunity. Can you talk about that and whether you see any validity or risk to this?

Andrew Robbins, Board Member

Yeah, again, we're going to fall back to what do the clinical data say. And so I feel very confident saying that we have characterized the results of both the Summit and the APEX study in non-advanced and advanced mastocytosis patients thoroughly and completely. There is no hidden data, no smoking gun, nothing that you should expect to see. The data that we've presented is representative of what happened in those trials. What I can also tell you is that working very closely with many physicians in the community, they have an expectation. That they will monitor patients who are receiving beziclacinib, especially early in the initiation of treatment, as almost all of our higher-grade transaminase elevations presented within the first several cycles. So I think there's a little bit of a focus on what a document is going to say as opposed to what's going to happen in the commercial setting. We know in the commercial setting that the drug will be used. We know that patients will be tested. We also know that the significant majority of prescribers, even in the non-advanced systemic mastocytosis space, are hematologists. Hematologists are not shy about measuring blood labs and blood levels, both for safety as well as for signs of efficacy. So even in a scenario that you could construct without monitoring language, I'm confident that our drug will be monitored from a workflow perspective. We see no impediment to use from a monitoring claim.

Faisal Khashid, Analyst — Jefferies

Got it. And in terms of the differences in the indications and opportunity here between GIST and SM, are you considering going for different brands between the two indications, and does it matter?

Andrew Robbins, Board Member

In order to make that determination, you need to do it at the time you submit your NDA. So we have made that determination long ago. We've suggested that once we receive an approval, we'll lay out our marketing strategy. There are, I think, slight pros and cons to each of the two cases, one where we have a singular brand across all of the indications, one where we have brands that are specific to, for instance, just in the mastocytosis community. I don't think it's, whichever way we've decided, and I'll be happy to tell you, hopefully in the very near future when we secure an approval, I don't think that that will have any dramatic effect on the commercial ramp or uptake of bezuclacinib.

Faisal Khashid, Analyst — Jefferies

Got it. And then, Andy, just to clarify, though, I think in the past you told me that this would be a single sales force for the drug. Does that play into this decision on one versus two brands?

Andrew Robbins, Board Member

Not at all. So we have hired a sales force. They will be asked to be responsible across the board for all the indications, advanced, non-advanced, mastocytosis, as well as GIST. The reason we did that is not because the individual physician call points are the same. They're obviously distinct with sarcoma experts, solid tumor oncologists as the traditional treaters of GIST patients, Whereas hematologists, and then we'll call them complex or academic allergists, as the most likely treaters of mastocytosis patients. But what's very interesting is that the addresses, the buildings, the places of work, that both of those physicians work is often the same building, the same site. So sending a cogent representative or small cogent team, they can cover all of those indications, all of those disease treaters in the same place. So that's really the focus of the sales team.

Faisal Khashid, Analyst — Jefferies

Got it. And if I can ask this question in a slightly different way. So the doses that you're using are quite different, right? It's 100 mg in SM compared to 600 in GIST. Just from a logistical perspective of tablets and the vials and how you price this, how could you even pull this off as one brand?

Andrew Robbins, Board Member

Well, I'll point to a drug, Avakit, which has an approval in PDGFR, just advanced systemic mastocytosis and non-advanced as a single brand with very different doses by each of those indications, and they have what's known as flat pricing. So a bottle of Avakit using a 25-milligram dose is priced at the same level as a bottle of Avakit at a 300-milligram dose with, you know, obviously very different amounts of total volume of the drug. The key here in these very rare diseases for relatively high-priced oral therapeutics is that the supply chain for first Blueprint and then Sanofi and then hopefully very soon for us as Cogent is more tightly controlled. So you can have a good line of sight through a distributor or a pharmacy to the exact patient you're treating. Physicians also, in order to secure reimbursement, have to be very precise at their diagnosis in the disease that the patient has. You can't just write down, I want some bezuclastinib. You're going to need to go through a process to select exactly which disease someone has. And so when you select that a patient has, in the case of Avacit, non-advanced systemic mastocytosis, then you can't submit that claim and order a bottle of pills for PDGFR GIST, as an example. So the way that the drug is reimbursed and the way that the supply chain is controlled makes it very possible in these situations to have much more control.

Faisal Khashid, Analyst — Jefferies

Got it. Okay. And then with respect to the GIST launch dynamics, you mentioned your commercial readiness. And as you mentioned, the Salesforce hired, I think you've disclosed that you guys have an EAP program that is open. Can you talk about the level of interest in that program and the extent to which that should help the early commercial launch?

Andrew Robbins, Board Member

Yes, you're absolutely correct. Since the availability of the pivotal trial results, we've opened expanded access programs here in the states for patients across all three indications. We can tell you that at the sites that are participating, we've had very strong interest from patients. And we have, obviously, many patients on the Expanded Access Program. Once we get to an approval, one of the key strategic imperatives for a successful launch will be, like many other companies, to transition patients from the Expanded Access Program to commercial drug. And that's, you know, one of the early focuses of the commercial strategy. We also know, through talking with patients, patient advocates, as well as physicians who are either at sites who don't want to participate in the EA, The EAP is a little bit like a clinical trial from a preparation at a site perspective. There are many doctors and many patients who don't have the convenient logistics to get to an EAP site that would want to participate, and we're very much looking forward to an approval to reach those patients as soon as possible.

Faisal Khashid, Analyst — Jefferies

Got it. And then can you talk about the SM opportunity and how you're thinking about the various patient groups here? Obviously, there is a drug that is approved in non-advanced SM. How are you thinking about the opportunity between potentially capturing patients, switching patients off of Avacit versus, you know, patients that may have tried and failed Avacit versus kind of de novo patients?

Andrew Robbins, Board Member

Right. Within the non-advanced systemic mastocytosis patient population, of the patients that are diagnosed, and maybe we'll pause there for a second, diagnosis in this disease is a real challenge for patients who often spend years and many, many physician referrals waiting to get confirmation of the name of the disease that's causing them all of their morbidity, their significant symptomatic problems. So they have a journey, and we hear this consistently of, again, several years and several doctors before they figure out what actual disease they have. We believe that there's about 3,000 to 3,500 patients who have been confirmed diagnosed with moderate to severe non-advanced systemic mastocytosis, which is really our target patient population. And we think about those patients within kind of three distinct buckets today, those that are still taking evapritinib, those that used to take evapritinib, and those that are afraid to take evapritinib or reticent to take evapritinib based on some of the known and talked about CNS toxicities primarily that can affect patients who take that drug. This is a prevalence disease. There's relatively few patients who are newly diagnosed on a monthly or quarterly basis compared to that installed base of patients who are either taking, used to take, or don't want to take avipritinib. So that really will be the focus, certainly in the early years of the cogent commercial launch, is communicating with those patients and their health care providers about the potential benefits of bezuclacinib compared to what they're either used to on avipritinib or what they're maybe afraid of on avipritinib.

Faisal Khashid, Analyst — Jefferies

Got it. And then in terms of sizing these three groups, what proportion of these kind of 3,000 to 3,500 patients are split across these three groups?

Andrew Robbins, Board Member

Yeah, we think it's probably something like two-thirds on, one-third either used to take or afraid to take in that ballpark. We also understand that there are many patients that are not yet diagnosed, that we will join the efforts of Sanofi, who's working on this already and has been for several years, to spread disease awareness, to find the patients, to help them navigate this journey, to get an affirmative diagnosis. But one of the things that's really exciting, and we haven't shown this yet, is we ran a subsequent study after the Summit Pivotal, which is known now, I think, among the investment community as the Summit SWITCH trial, where we found patients who have been taking avipritinib, either the 25-milligram labeled dose or one dose higher, the 50-milligram dose, and we enrolled them in our study. We used our own patient-reported outcome tool to test their total symptom score and establish that as a baseline, and then after a short washout, we administered bezuclacinib, and for the first time at ASH in a few weeks, and then as additional scientific meetings follow, we're going to report results from that study, and that, I think, will be very illustrative and informative for patients who are currently taking avapritinib to see, Is there any reason why I, who might identify with some of the patients in this new study, could benefit from switching to bezuclostinib? I think that'll be really, really interesting data.

Faisal Khashid, Analyst — Jefferies

Got it. And then can you just level set expectations for how many patients that will be? And is this something that could at some point make it onto the label?

Andrew Robbins, Board Member

It was about a 30-patient study. I don't know, you know, as far as making it onto the label, I think from our perspective, when we see the results, which we haven't seen fully, if they are consistent with the summit pivotal study, that we will find a way to communicate those results effectively to healthcare providers and potentially patients as well. But I really think whether that's via a medical communication or a commercial communication, these results could have the potential to really change how people think about the benefit of moving from avapritinib to bezuclastinib.

Faisal Khashid, Analyst — Jefferies

Got it. And then I want to spend a few minutes on your pipeline as well. At EHA, you showed some really interesting preclinical data for a selective JAK2 V617 drug that should be entering the clinic soon. Can you talk about the promise of that program, how you're seeing that kind of fitting in with Cogent strategically and also timelines to data?

Andrew Robbins, Board Member

Yes. So our JAK V617F program is still on track for IND this year, so within a small number of weeks, we would expect to file that IND. It is specifically designed as really the first test of a true selective V617F inhibitor over wild type JAK, JAK2 or JAK1, and while there are other drugs in development, probably namely an Ajax drug that was acquired by Lilly as well as kind of a portfolio of Insight's earlier stage efforts to go after this target, we will be the first clinical test of a very selective version of this drug. So when you look at the results that were presented at EHA this past summer from Ajax, which is probably on the order of three or four times selective for mutant over wild type, whereas we're well over 100 times selective for mutant over wild type, they showed what I would say their clinical data was encouraging improvement in symptomology, encouraging improvement in reduction of spleen volume, but really not very encouraging reduction in variant allele frequency, and a very high rate of high-grade, grade 3-4 hematologic toxicity, and that is exactly the profile you'd expect from an inhibitor of wild-type JAK on top of some activity of the mutant. We believe by sparing the wild-type activity, the profile of our drug would be able to significantly reduce the hematologic toxicity, unlocking the therapeutic index, allowing us to dose high enough to really move that varying allele frequency And do something analogous to what we've shown with bezicoacinib and mastocytosis, that a potent inhibitor of a clonal disease can impact patient outcomes by removing the mutant cells from the body. And that is and should be the ultimate goal in these diseases, like mastocytosis and these MPNs, of removing the mutant cells that are causing the problem, in addition to measuring how does a patient feel.

Faisal Khashid, Analyst — Jefferies

Got it. And then maybe just one last question going back to this class. I'm sorry, Andy. In terms of the launch that you guys are going to embark on in 2027, I mean, as an analyst looking at a lot of these launches, I feel like your launch has several aspects that should make it a very strong launch out of the gate. In GIST, you have the EAP open. You have strong data in general, but then you also recently presented switch data, basically, crossover, so you can add it on in a third-line setting. And then SM, you just talked about the switch data that you'll share, and you also mentioned that there's kind of this patients who know they have the disease, but they're scared to try Evacate. That can almost be like a bolus, right? So shouldn't this launch go amazingly next year?

Andrew Robbins, Board Member

I mean, from your lips to God's ears, right? So we agree, especially in GIST, the dynamics. The one thing you forgot, I'll just add another one for you. There's really no competition right now in Second Line GIST. The standard of care is a generic drug that we're adding on top of, so we don't need to replace it. We need to add to it. And from a share of voice perspective, we'll be the only company out promoting a drug for imatinib-resistant GIST patients. So I think that that's another sort of net benefit. I do think that the gist launch should go very well and be very rapid. I think on the massocytosis side, a lot of our efforts are going to be very focused on patient communication, creatively helping patients understand that they have another option. And sometimes launches like that are a little slower from the beginning than a traditional healthcare provider launch. But our team is up for the challenge and really feel strongly that the benefits of bezuclacinib are Thank you, Andy.

Faisal Khashid, Analyst — Jefferies

And then maybe just to kind of wrap us up here, I think you've had a very busy day of meetings. Can you just tell us what was the best question you got? What was the worst question you got? And then any closing remarks that you have?

Andrew Robbins, Board Member

Well, your question about how good your launch was going to be is my favorite question because I agree with it very much. You know, I think a lot of people really do understand the story and are trying to get their heads around preparing for launch, how fast the launch is going to go. But we certainly appreciate a lot of the support from our historical long holders. We feel it, and we want to make you proud, as well as obviously patients and their families. So very much looking forward to hopefully a very near-term approval.

Faisal Khashid, Analyst — Jefferies

Got it. That was a very polite answer to the question, but thank you so much, Andy, for being here today. Yeah, thanks, Faisal. Thank you.